Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18]F-PSMA-1007 PET/CT in Metastatic Prostate Cancer
NCT05712174Phase 2Terminated
- Sponsor
- American Health Staffing Group
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radelumin in prostate cancer (PCa), sponsored by American Health Staffing Group. Primary endpoint: Questionnaire based assessment of the impact of [18]F-PSMA-1007 PET/CT or PET/MRI on patient management plans. Started Sep 2023; status: terminated.
02
Drugs
radelumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05712174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712174.